AstraZeneca Market Value Drops £20 Billion After Drug Trial Failure

Shares of AstraZeneca fell by as much as 11% on July 9, 2026, erasing more than £20 billion from the company's market value. The decline followed the failure of the CARDIO-TTRansform late-stage clinical trial for Wainua, a heart disease drug developed in partnership with Ionis Pharmaceuticals. The trial, which involved 1,432 patients over 140 weeks, failed to meet its primary objective of reducing cardiovascular deaths and recurring heart problems in patients with transthyretin-mediated amyloid cardiomyopathy when added to standard care.

The stock drop pushed AstraZeneca's market value below the £200 billion threshold and dragged the FTSE 100 index down by 0.8%. Analysts from Jefferies and Citi noted the failure removes a significant revenue stream, with estimated peak sales losses between $2 billion and $6 billion. Jefferies reported that a 24% increase in the use of the rival drug tafamidis during the study likely complicated the results, although patients using Wainua alone saw a 29% reduction in events.

Despite the setback, analysts suggest the company's 2030 goal of reaching $80 billion in annual revenue remains intact. Investors are now focusing on the upcoming results of the AVANZAR lung cancer trial expected in July or August. Sharon Barr, Executive Vice President of Biopharmaceuticals R&D, stated that while the objective was not met, the results support a greater scientific understanding of treatment for the condition.